Table 3.
Clinical trials for BL with SCNSL
| Study | Regimen | N | CNS involvement, % | Survival for all patients, % | Survival for patients with CNS involvement | TRM of all patients, % | CNS relapse, % |
|---|---|---|---|---|---|---|---|
| UKLG LY06118 | CODOX-M IVAC |
52 | 13 | 2-y EFS, 65 2-y OS, 73 |
1-y, 100 | 6 | NR |
| AMC048119 | R-CODOX-M R-IVAC |
34 | 12 | 1-y PFS, 69 2-y OS, 69 |
NR | 3 | 3 |
| NCT00001337120 | DA-EPOCH-R | 19 | 5 | FFP, 95 OS, 100 |
OS, 100 | 0 | 0 |
| NCT0109218232 | DA-EPOCH-R | 113 | 10 | 4-y EFS, 84 4-y OS, 87 |
4-y EFS, 45 | 4 | 3 |
| MDACC single-arm study121 | HyperCVAD-R | 31∗ | 6 | 3-y EFS, 80 3-y OS, 89 |
3-y OS, 50 | NR | 0 |
| Retrospective study114 | HyperCVAD-R | 54 | 28 | 5-y RFS, 59 5-y OS, 55 |
5-y RFS, 26 5-y OS, 23 |
15 | 4 |
DA-EPOCH-R, dose-adjusted infusional EPOCH-R; EFS, event-free survival; FFP, freedom from progression; MDACC, MD Anderson Cancer Center; NR, not reported; RFS, relapse-free survival; TRM, treatment-related mortality.
∗
BL, n = 17 (55%) and B-cell acute lymphoblastic leukemia, n = 14 (45%).